Phenomix

About Phenomix

Phenomix Sciences operates as a precision medicine biotechnology firm focused on the obesity market. The company was founded in 2017 by Dr. Andres Acosta and Dr. Michael Camilleri, both physicians and researchers from the Mayo Clinic. Their foundation stemmed from a decade of clinical research aimed at understanding the varied responses of individuals to obesity treatments. Dr. Acosta's journey began in medical school, where he recognized that obesity was the primary driver of preventable cardiometabolic diseases, motivating him to seek more effective solutions.

The core of Phenomix's business is providing data intelligence to guide the treatment of obesity. The company's main offering is the MyPhenome™ test, a product that started as a blood test and has evolved to use a simple saliva swab. This test analyzes a patient's genomics, metabolomics, and hormone levels to identify their specific obesity phenotype—the subtype of obesity driven by the interaction of their genes and environment. Phenomix has identified key phenotypes such as "Hungry Gut" (a defect in satiety), "Hungry Brain" (a defect of satiation), and "Emotional Hunger". By identifying a patient's primary phenotype(s), the test provides healthcare providers with the necessary information to create personalized and more effective treatment plans. These plans can include targeted diet and lifestyle interventions, as well as specific recommendations for medications like GLP-1s or medical procedures. Research has shown that treatment guided by this phenotyping can nearly double a patient's weight loss results.

Phenomix operates on a business-to-business model, serving obesity specialists, healthcare providers, pharmaceutical companies, and payers. Revenue is generated through the sale of its MyPhenome™ tests. The company is accelerating the commercialization and adoption of its tests within the obesity specialist market and the broader industry. The company exclusively licenses the underlying technology from the Mayo Clinic, a result of the founders' extensive research. Since its inception, Phenomix has raised a total of $7.65 million in funding over several rounds, including a Series A round that secured $5.5 million from investors like DexCom and Labcorp, and a $2.3 million grant from the National Institutes of Health (NIH). This capital is being used to expand the adoption of its tests, support further clinical research, and develop new products.